EcoDrugPlus

Cystic Fibrosis Transmembrane Conductance Regulator

Ensembl ID : ENSMSIG00000020275
Gene Symbol: CFTR
1 Cross references
231 Possible Orthologues:

Cytochrome P450, Family 17, Subfamily A, Polypeptide 1

Ensembl ID : ENSMSIG00000011019
Gene Symbol: CYP17A1
1 Cross references
225 Possible Orthologues:

Cytochrome P450, Family 19, Subfamily A, Polypeptide 1

Ensembl ID : ENSMSIG00000003500
Gene Symbol: CYP19A1
1 Cross references
330 Possible Orthologues:

Cytochrome P450, Family 26, Subfamily A, Polypeptide 1

Ensembl ID : ENSMSIG00000000405
Gene Symbol: CYP26A1
1 Cross references
222 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 11

Ensembl ID : ENSMSIG00000027650
Gene Symbol: CYP3A11
1 Cross references
644 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 13

Ensembl ID : ENSMSIG00000007363
Gene Symbol: CYP3A13
1 Cross references
642 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 16

Ensembl ID : ENSMSIG00000005776
Gene Symbol: CYP3A16
1 Cross references
649 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 57

Ensembl ID : ENSMSIG00000022124
Gene Symbol: CYP3A57
1 Cross references
637 Possible Orthologues:

Cytochrome P450, Family 46, Subfamily A, Polypeptide 1

Ensembl ID : ENSMSIG00000014395
Gene Symbol: CYP46A1
1 Cross references
274 Possible Orthologues:

Dihydrofolate Reductase

Ensembl ID : ENSMSIG00000012568
Gene Symbol: DHFR
1 Cross references
368 Possible Orthologues:

Dihydroorotate Dehydrogenase

Ensembl ID : ENSMSIG00000017663
Gene Symbol: DHODH
1 Cross references
188 Possible Orthologues:

Dipeptidylpeptidase 4

Ensembl ID : ENSMSIG00000014416
Gene Symbol: DPP4
1 Cross references
297 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).